February 24th 2025
The European Commission has approved Biocon Biologics’ YESINTEK, a biosimilar referencing Janssen Biotech’s Stelara (ustekinumab).
February 19th 2025
Vimkunya was granted approval under priority review based on positive results from two Phase III trials.
February 19th 2025
Ospomyv, or Obodence in the EU, and Xbryk were approved for all indications referencing Prolia and Xgeva, respectively.
February 19th 2025
This expanded label allows IZERVAY (avacincaptad pegol intravitreal solution) to be used without a limitation on duration of dosing for treating geographic atrophy.
February 19th 2025
The vaccine combines the antigenic components of two previously well-established meningococcal vaccines made by GSK.
2 Commerce Drive
Cranbury, NJ 08512